Haemopoietic growth factors in aplastic anaemia: a cautionary note. European Bone Marrow Transplant Working Party for Severe Aplastic Anaemia.
We are concerned about the inappropriate use of haemopoietic growth factors in patients with severe aplastic anaemia (SAA). The treatment of choice for this disorder is bone-marrow transplantation from an HLA-identical sibling donor if the patient is younger than 45 years, but it must be done soon after onset before the patient becomes sensitised by multiple red-cell and platelet transfusions. Other patients should receive immunosuppressive therapy with antithymocyte globulin alone or with cyclosporin or oxymetholone. Haemopoietic growth factors may have a role in stimulation of granulopoiesis after immunosuppressive therapy, but there is no evidence that they can correct the underlying stem-cell defect in SAA, and therefore no justification for their use alone in newly diagnosed SAA. Such treatment is harmful because it delays bone-marrow transplantation, or immunosuppressive therapy in older patients and those without suitable donors, thus reducing the chances of a successful outcome.
Marsh
J C
JC
Department of Haematology, St George's Hospital, London, UK.
Socie
G
G
Schrezenmeier
H
H
Tichelli
A
A
Gluckman
E
E
Ljungman
P
P
McCann
S R
SR
Raghavachar
A
A
Marin
P
P
Hows
J M
JM
D000367:Age Factors; D000741:Anemia, Aplastic / Q000628:therapy*; D016026:Bone Marrow Transplantation; D016298:Hematopoietic Cell Growth Factors / Q000627:therapeutic use*; D006801:Humans; D013997:Time Factors
D016298:Hematopoietic Cell Growth Factors